NYSE · MDT
Medtronic Plc
$97.11+$2.33 (+2.46%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
Loading market information…
NASDAQ · LIVN · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
LivaNova PLC’s quoted price sits in the upper half of its reported 52-week range, 5.26% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
LivaNova PLC’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $1.06. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow LivaNova PLC’s reporting calendar.
THE COMPANY BEHIND THE TICKER
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:58 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 7, 2025 |
| $0.88+17.33% vs estimate |
| $316.90M+4.79% vs estimate |
| Q4 2024 | Feb 25, 2025 | $0.81+1.25% vs estimate | $321.80M+4.26% vs estimate |
|---|
| Q3 2024 | Oct 30, 2024 | $0.90+26.76% vs estimate | $318.12M-1.71% vs estimate |
|---|
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 6 contributors · Median target $92.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$97.11+$2.33 (+2.46%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
$94.44+$2.66 (+2.9%)
Edwards Lifesciences Corporation’s quoted price sits in the upper half of its reported 52-week range, 1.92% below the high.
$252.83+$2.66 (+1.06%)
ResMed Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.95% below the high.
$119.79+$1.47 (+1.24%)
Haemonetics Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.22% below the high.
$71.18+$0.21 (+0.3%)
Inspire Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.59% below the high.
$13.01+$0.08 (+0.62%)
NeuroPace, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.62% below the high.
$11.27-$0.52 (-4.41%)
Mobia Medical, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 26.29% below the high.
